Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition.

Abstract

Because P-glycoprotein (P-gp) plays an absorptive role in the skin, its pharmacological inhibition represents a strategy to promote cutaneous localization of anticancer agents that serve as its substrates, improving local efficacy while reducing systemic exposure. Here, we evaluated the ability of a nanoemulsion (NE) coencapsulating a P-gp inhibitor… (More)
DOI: 10.1016/j.xphs.2017.09.007

Topics

Cite this paper

@article{Giacone2017EvidenceTP, title={Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition.}, author={Daniela V Giacone and Vanessa F M Carvalho and Soraia K{\'a}tia Pereira Costa and Luciana Biagini Lopes}, journal={Journal of pharmaceutical sciences}, year={2017} }